Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Astrocytoma, Grade IV Clear all
Terminated Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

AMG 595 First-in-Human in Recurrent Gliomas

NCT01475006
View directory record Official record
Conditions
Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
Interventions
AMG 595
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 14, 2026, 4:57 PM EDT
Terminated Phase 2 Interventional Results available

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

NCT01113463
View directory record Official record
Conditions
Brain Cancer
Interventions
TPI 287
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 14, 2026, 4:57 PM EDT
Not listed Early Phase 1 Interventional

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

NCT04315584
View directory record Official record
Conditions
Glioblastoma
Interventions
Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00004147
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
incyclinide
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00335764
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
sorafenib tosylate, erlotinib hydrochloride, tipifarnib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 14, 2026, 4:57 PM EDT
Terminated Phase 1 Interventional

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 14, 2026, 4:57 PM EDT
Recruiting Early Phase 1 Interventional

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

NCT07076472
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-Guided Focused Ultrasound Ablation, Oral Aminolevulinic Acid Hydrochloride
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma
Interventions
Vandetanib and Etoposide
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 14, 2026, 4:57 PM EDT
Not yet recruiting Early Phase 1 Interventional

Oral Gallium Maltolate for Recurrent Glioblastoma

NCT07515924
View directory record Official record
Conditions
Glioblastoma
Interventions
Gallium Maltolate, Surgical Intervention
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

NCT00008008
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
2
States / cities
Paterson, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

NCT03744026
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
SonoCloud-9, Carboplatin
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 14, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07464925
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Interventions
GLIX1
Drug
Lead sponsor
Tetragon Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 4:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT01189240
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

NCT01435395
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, bevacizumab and bortezomib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

NCT00005813
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bispecific antibody MDX447, lymphokine-activated killer cells, conventional surgery
Biological · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

NCT01856933
View directory record Official record
Conditions
GBM, Glioblastoma Multiforme, Gliosarcoma
Interventions
PSMA ADC
Drug
Lead sponsor
Heinrich Elinzano, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

NCT00006025
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors

NCT00003574
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
surgical procedure, brachytherapy, intraoperative radiation therapy, iodine I 125
Procedure · Radiation
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 14, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

NCT00597493
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Sorafenib and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 14, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

NCT00036972
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 14, 2026, 4:57 PM EDT